ACRS (Aclaris Therapeutics) Total Assets : $220.33 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Aclaris Therapeutics Total Assets?

Aclaris Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was $220.33 Mil.

Warning Sign:

If a company builds assets at 38.6% a year, faster than its revenue growth rate of 29% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Aclaris Therapeutics's average Total Assets Growth Rate was 36.30% per year. During the past 3 years, the average Total Assets Growth Rate was 21.30% per year. During the past 5 years, the average Total Assets Growth Rate was 38.60% per year. During the past 10 years, the average Total Assets Growth Rate was 30.40% per year.

During the past 12 years, Aclaris Therapeutics's highest 3-Year average Total Assets Growth Rate was 253.10%. The lowest was -30.50%. And the median was 21.30%.

Total Assets is connected with ROA %. Aclaris Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 was -191.80%. Total Assets is also linked to Revenue through Asset Turnover. Aclaris Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 was 0.05.

Aclaris Therapeutics Total Assets Historical Data

The historical data trend for Aclaris Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Total Assets Chart

Aclaris Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

70.78

251.21

254.60

197.41

220.33

Aclaris Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															197.41	174.07	161.07	182.39	220.33

Aclaris Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aclaris Therapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	155.554	+	64.773
	=	220.33

Aclaris Therapeutics's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	155.554	+	64.773
	=	220.33

Aclaris Therapeutics (NAS:ACRS) Total Assets Explanation

Total Assets is connected with ROA %.

Aclaris Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-386.208	/	( (182.394	+	220.327)	/ 2 )
	=	-386.208	/	201.3605
	=	-191.80 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aclaris Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	9.211	/	( (182.394	+	220.327)	/ 2 )
=	9.211	/	201.3605
=	0.05

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aclaris Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclaris Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (NAS:ACRS) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

0H8T:UK 8AT:Germany

Address

701 Lee Road, Suite 103, Wayne, PA, USA, 19087

Website

https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Executives

Anand Mehra	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Joseph Monahan	officer: Chief Scientific Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Kevin Balthaser	officer: Chief Financial Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
James Loerop	officer: Chief Business Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Douglas J. Manion	officer: Pres and COO	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Neal Walker	director, officer: President and CEO	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Andrew N Schiff	director	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Gail Cawkwell	officer: Chief Medical Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Frank Ruffo	officer: Chief Financial Officer	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
David N. Gordon	officer: Chief Medical Officer	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Kamil Ali-jackson	officer: Chief Legal Officer	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
James B. Tananbaum	10 percent owner	3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
Foresite Capital Management Iii, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iii, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund Iv, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111